The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.
breast cancer
ductal carcinoma in situ (DCIS)
neoadjuvant chemotherapy (NAC)
pathological complete response (pCR)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2021
10 Jan 2021
Historique:
received:
12
11
2020
revised:
25
12
2020
accepted:
06
01
2021
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
epublish
Résumé
A ductal in situ (DCIS) component is often associated with invasive breast carcinoma (BC), and its effect on response to treatment is unknown. We assessed the predictive value of the DCIS component for pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). We analyzed a cohort of 1148 T1-3NxM0 breast cancer (BC) patients treated by NAC at Institut Curie between 2002 and 2012. The presence of a DCIS component was retrospectively recorded from both the pre-NAC biopsy pathological report and surgical specimens. We included 1148 BC patients treated by NAC for whom pre- and post-NAC data concerning the in situ component were available. DCIS was present before NAC in 19.6% of the population. Overall, 283 patients (19.4%) achieved pCR after NAC. There was no significant association between the presence of DCIS on pre-NAC biopsy and pCR. In a multivariate analysis including subtype, tumor size, grade, mitotic index, and Ki67 index, only BC subtype (luminal/TNBC/
Identifiants
pubmed: 33435265
pii: cancers13020235
doi: 10.3390/cancers13020235
pmc: PMC7827327
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
Ann Oncol. 1998 Nov;9(11):1179-84
pubmed: 9862047
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Br J Cancer. 2010 Apr 27;102(9):1391-6
pubmed: 20424617
J Breast Cancer. 2014 Dec;17(4):376-85
pubmed: 25548587
J Clin Oncol. 2008 Feb 10;26(5):778-85
pubmed: 18258986
Oncol Res Treat. 2014;37(10):563-8
pubmed: 25486071
J Clin Oncol. 1992 Apr;10(4):599-605
pubmed: 1548522
J Clin Oncol. 1999 May;17(5):1474-81
pubmed: 10334533
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Breast Cancer. 2002;9(1):75-81
pubmed: 12196726
Breast Cancer Res Treat. 2012 Apr;132(3):863-70
pubmed: 21667238
Oncol Rep. 2002 Sep-Oct;9(5):1027-31
pubmed: 12168068
Breast Cancer Res Treat. 2016 Jul;158(1):179-187
pubmed: 27318854
BMC Cancer. 2011 Nov 14;11:486
pubmed: 22081974
Diagn Pathol. 2017 Feb 21;12(1):20
pubmed: 28222768
Med Oncol. 2012 Sep;29(3):1536-42
pubmed: 21983862
PLoS One. 2014 Dec 12;9(12):e115103
pubmed: 25501357
Breast Cancer Res. 2020 Mar 26;22(1):32
pubmed: 32216826
J Clin Oncol. 1995 Mar;13(3):547-52
pubmed: 7884414
Breast. 2017 Apr;32:237-244
pubmed: 27318645
Eur J Surg Oncol. 2017 Aug;43(8):1415-1420
pubmed: 28526187
Breast Cancer Res Treat. 2010 Nov;124(1):133-40
pubmed: 20697801
Ann Diagn Pathol. 2020 Dec;49:151634
pubmed: 32987254